Current and emerging data on SGLT2 inhibitors in heart failure

Current and emerging data on SGLT2 inhibitors in heart failure

These videos were funded by an unrestricted educational grant from AstraZeneca

The following videos are pending submission to the European Board for Accreditation in Cardiology (EBAC). Once accredited, the full programme will be available on www.radcliffeeducation.com

  • Understand the SGLT-2 inhibitor cardiovascular outcome trial (CVOT) data
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT-2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

 

SGLT2 in HF now and the future
Prof Andrew Coats, University of Warwick, Warwick, UK
Prof Carolyn Lam, National Heart Centre Singapore, SG
 
Watch Interview
Medtronic sponsored sessions at EHRA 2018 - Dr Jack McCready & Felicity Champney, RN

09.54 mins

 
DAPA-HF: Clinical trial design rationale
Dr Felipe Martinez, National University of Cordoba, Cordoba, AR
 
Watch Interview
AF ablation efficiency and outcomes - Dr Aaisha Opel

05.09 mins

 
SGLT2i beyond diabetes
Prof Lars Lund, Karolinska University Hospital, Stockholm, SE
 
Watch Interview
AF ablation efficiency and outcomes - Dr Aaisha Opel

08.05 mins

 
SGLT2'S: Current guidelines, recent data & future practices
Prof Andrew Coats, University of Warwick, Warwick, UK
Prof Scott Solomon, Harvard Medical School, MA, US
 
Watch Interview
AF ablation efficiency and outcomes - Dr Aaisha Opel

10.15 mins

 
DAPA-HF: The dapaglifozin and prevention of adverse outcomes in heart failure trial
Prof Frank Ruschitzka, University Hospital Zurich, Zurich, CH
 
Watch Interview
AF ablation efficiency and outcomes - Dr Aaisha Opel

05.17 mins

DAPA-HF: A discussion with the trialist
Prof John McMurray, University of Glasgow, UK
Prof Mikhail Kosiborod, University of Missouri, MO, US
 
Watch Interview
AF ablation efficiency and outcomes - Dr Aaisha Opel

19.18 mins